Wegovy and Zepbound are the only highly effective GLP-1 weight-loss drugs sold mainly in the US as weekly injections. (Photo: Reuters)

US President Donald Trump on Thursday announced that his administration has reached agreements with Eli Lilly and Novo Nordisk to bring down the prices of popular GLP-1 weight-loss drugs. Making the announcement at a White House event, Trump said the prices of Zepbound and Wegovy will be reduced for government programs such as Medicare and Medicaid, as well as for cash payers.

US customers pay more for prescription drugs

The move is aimed at increasing access to the treatments through US Medicare for people aged 65 and over and the Medicaid program for low-income people, which together provide healthcare coverage for nearly half of all Americans.

Pati

See Full Page